{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:04:17Z","timestamp":1789038257308,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/bmt.2016.322","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T10:25:26Z","timestamp":1482143126000},"page":"580-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients"],"prefix":"10.1038","volume":"52","author":[{"given":"B S","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P F","family":"Thall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B C","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D R","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Al-Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gulbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q H","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kawedia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L L","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fernandez-Vina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E J","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R B","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,19]]},"reference":[{"key":"BFbmt2016322_CR1","first-page":"3","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation","author":"ED Thomas","year":"2009","unstructured":"Thomas ED. A history of allogeneic hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas\u2019 Hematopoietic Cell Transplantation, 4th edn. Wiley-Blackwell: Oxford, UK, 2009, pp 3\u20137."},{"key":"BFbmt2016322_CR2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","volume":"49","author":"ED Thomas","year":"1977","unstructured":"Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Elurnoy N et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511\u2013533.","journal-title":"Blood"},{"key":"BFbmt2016322_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","volume":"8","author":"JA Russell","year":"2002","unstructured":"Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468\u2013476.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M de Lima","year":"2004","unstructured":"de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857\u2013864.","journal-title":"Blood"},{"key":"BFbmt2016322_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bbmt.2007.03.003","volume":"13","author":"JA Russell","year":"2007","unstructured":"Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400cGy total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814\u2013821.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","volume":"14","author":"BS Andersson","year":"2008","unstructured":"Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclosphosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS. Biol Blood Marrow Transplant 2008; 14: 672\u2013684.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/bmt.2010.190","volume":"46","author":"J Pidala","year":"2011","unstructured":"Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J et al. Targeted i.v. BU and fludarabine (t-i.v. BU\/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant 2011; 46: 641\u2013649.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016322_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","volume":"18","author":"JB Perkins","year":"2012","unstructured":"Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1099\u20131107.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-6-15","volume":"6","author":"H Liu","year":"2013","unstructured":"Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol 2013; 6: 15.","journal-title":"J Hematol Oncol"},{"key":"BFbmt2016322_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2015; 16: 1525\u20131536.","journal-title":"Lancet Oncol"},{"key":"BFbmt2016322_CR11","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31\u201342.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016322_CR12","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","volume":"89","author":"JT Slattery","year":"1997","unstructured":"Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055\u20133060.","journal-title":"Blood"},{"key":"BFbmt2016322_CR13","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225\u2013230.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016322_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477\u2013485.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","volume":"14","author":"M Geddes","year":"2008","unstructured":"Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220\u2013228.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.bbmt.2013.07.002","volume":"19","author":"JA Russell","year":"2013","unstructured":"Russell JA, Kangarloo SB, Williamson T, Chaudhry MA, Savoie ML, Turner AR et al. Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. Biol Blood Marrow Transplant 2013; 19: 1381\u20131386.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","volume":"13","author":"T Madden","year":"2007","unstructured":"Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D et al. Pharmacokinetics of once daily IV busulfan as part of pretransplant preparative regimens; a comparison with an every 6 hour dosing schedule. Biol Blood Marrow Transplant 2007; 13: 56\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR18","doi-asserted-by":"crossref","unstructured":"Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO et al. Allogeneic transplantation for myelofibrosis: benefit of dose intensity. J Clin Oncol 2013; 31 (suppl): (abstract 7011).","DOI":"10.1200\/jco.2013.31.15_suppl.7011"},{"key":"BFbmt2016322_CR19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079\u20132088.","journal-title":"Blood"},{"key":"BFbmt2016322_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","volume":"6","author":"BS Andersson","year":"2000","unstructured":"Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548\u2013554.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145\u2013154.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","volume":"17","author":"BS Andersson","year":"2011","unstructured":"Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL et al. Clofarabine\u00b1fludarabine with once daily iv busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011; 17: 893\u2013900.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/bmt.2012.114","volume":"48","author":"P Kebriaei","year":"2013","unstructured":"Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M et al. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 2013; 48: 26\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016322_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.bbmt.2010.07.016","volume":"17","author":"P Kebriaei","year":"2011","unstructured":"Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011; 17: 412\u2013420.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.bbmt.2012.05.011","volume":"18","author":"Y Nieto","year":"2012","unstructured":"Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplant in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant 2012; 18: 1677\u20131686.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR26","unstructured":"D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource: Los Angeles, CA, USA, 1997."},{"key":"BFbmt2016322_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.bmt.1701983","volume":"24","author":"D Przepiorka","year":"1999","unstructured":"Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, K\u00f6rbling M et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 763\u2013768.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016322_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bbmt.2014.04.003","volume":"20","author":"X Tang","year":"2014","unstructured":"Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M et al. Increasing Chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant 2014; 20: 1139\u20131144.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016322_CR29","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/1097-0142(19800415)45:8<2017::AID-CNCR2820450806>3.0.CO;2-C","volume":"45","author":"MJ Keating","year":"1980","unstructured":"Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G et al. Factors related to length of complete remission in adult acute leukemia. Cancer 1980; 45: 2017\u20132029.","journal-title":"Cancer"},{"key":"BFbmt2016322_CR30","unstructured":"Common Terminology Criteria v3.0. NIH Publication No. 03-5410, June 2003."},{"key":"BFbmt2016322_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/2340521","volume":"85","author":"RA Fisher","year":"1922","unstructured":"Fisher RA . On the interpretation of \u03c72 from contingency tables, and the calculation of P. J Royal Stat Soc 1922; 85: 87\u201394.","journal-title":"J Royal Stat Soc"},{"key":"BFbmt2016322_CR32","volume-title":"Introduction to the Theory of Nonparametric Statistics","author":"R Randles","year":"1979","unstructured":"Randles R, Wolfe D . Introduction to the Theory of Nonparametric Statistics. John Wiley, Hoboken, NJ, USA, 1979."},{"key":"BFbmt2016322_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/biomet\/38.1-2.141","volume":"38","author":"GH Freeman","year":"1951","unstructured":"Freeman GH, Halton JH . Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38: 141\u2013149.","journal-title":"Biometrika"},{"key":"BFbmt2016322_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Amer Statist Assoc 1958; 53: 457\u2013481.","journal-title":"J Amer Statist Assoc"},{"key":"BFbmt2016322_CR35","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163\u2013170.","journal-title":"Cancer Chemother Rep"},{"key":"BFbmt2016322_CR36","volume-title":"Bayesian Survival Analysis","author":"JG Ibrahim","year":"2004","unstructured":"Ibrahim JG, Chen M-Hui Sinha D . Bayesian Survival Analysis. Springer: New York, NY, USA, 2004."},{"key":"BFbmt2016322_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB . Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Amer Stat 1985; 39: 33\u201338.","journal-title":"Amer Stat"},{"key":"BFbmt2016322_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","volume":"15","author":"D Ho","year":"2007","unstructured":"Ho D, Imai K, King G, Stuart E . Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Pol Anal 2007; 15: 199\u2013236.","journal-title":"Pol Anal"},{"key":"BFbmt2016322_CR39","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752\u20131759.","journal-title":"Blood"},{"key":"BFbmt2016322_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","volume":"111","author":"FM Abu-Dahier","year":"2000","unstructured":"Abu-Dahier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190\u2013195.","journal-title":"Br J Haematol"},{"key":"BFbmt2016322_CR41","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3324\/haematol.2010.027516","volume":"95","author":"S Kurosawa","year":"2010","unstructured":"Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 2010; 95: 1857\u20131864.","journal-title":"Haematologica"},{"key":"BFbmt2016322_CR42","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GW, Tutschka PJ, Brookmayer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347\u20131353.","journal-title":"N Engl J Med"},{"key":"BFbmt2016322_CR43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","volume":"70","author":"PJ Tutschka","year":"1987","unstructured":"Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382\u20131388.","journal-title":"Blood"},{"key":"BFbmt2016322_CR44","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen\u2014a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31: 3549\u20133556.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016322_CR45","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","volume":"122","author":"EA Copelan","year":"2013","unstructured":"Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013; 122: 3863\u20137380.","journal-title":"Blood"},{"key":"BFbmt2016322_CR46","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013; 122: 3871\u20133878.","journal-title":"Blood"},{"key":"BFbmt2016322_CR47","first-page":"3580","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Nowak BJ, Keating MJ, Plunkett W . DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580\u20133589.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2016322_CR48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/em.20603","volume":"51","author":"BC Valdez","year":"2010","unstructured":"Valdez BC, Andersson BS . Interstrand crosslink inducing agents in pretransplantconditioning therapy for hematologic malignancies. Environ Mol Mutagen 2010; 51: 659\u2013668.","journal-title":"Environ Mol Mutagen"},{"key":"BFbmt2016322_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.leu.2404037","volume":"20","author":"A Shimoni","year":"2006","unstructured":"Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322\u2013328.","journal-title":"Leukemia"},{"key":"BFbmt2016322_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","volume":"104","author":"M De Lima","year":"2004","unstructured":"De Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865\u2013872.","journal-title":"Blood"},{"key":"BFbmt2016322_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.leukres.2015.04.009","volume":"39","author":"MA Kharfan-Dabaja","year":"2015","unstructured":"Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D et al. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: an analysis from the acute leukemia working party of the european group for blood and marrow transplantation. Leuk Res 2015; 39: 933\u2013937.","journal-title":"Leuk Res"},{"key":"BFbmt2016322_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/pgs.12.185","volume":"14","author":"M Hassan","year":"2013","unstructured":"Hassan M, Andersson BS . Role of pharmacogenetics in busulfan\/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 2013; 14: 75\u201387.","journal-title":"Pharmacogenomics"},{"key":"BFbmt2016322_CR53","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt2016322_CR54","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249\u20133257.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016322_CR55","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","volume":"32","author":"CG Kanakry","year":"2014","unstructured":"Kanakry CG, O\u2019Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014; 32: 3497\u20133505.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016322_CR56","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/bmt.2014.133","volume":"49","author":"MA Kharfan-Dabaja","year":"2014","unstructured":"Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socie G et al. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant 2014; 49: 1170\u20131175.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016322","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T04:46:23Z","timestamp":1718945183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,19]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFbmt2016322"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.322","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,19]]},"assertion":[{"value":"30 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BSA was previously a consultant for Otsuka America Pharmaceuticals, Inc., and REC has received research funding from Otsuka America Pharmaceuticals, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}